赤丹退黄颗粒调节肠道菌群影响NOD1/RIPK2通路促进胆汁淤积性肝损伤恢复
该研究用ANIT诱导的SD大鼠胆汁淤积性肝损伤模型,设对照组、模型组、熊去氧胆酸组和赤丹退黄颗粒组,发现赤丹退黄颗粒可改善肝功能和胆汁淤积指标、减少肝细胞凋亡和炎症,机制涉及调节肠道菌群、降低DAP代谢物、抑制NOD1/RIPK2通路。
要点
- 赤丹退黄颗粒改善ANIT大鼠肝功能和胆汁淤积指标。
- 赤丹退黄颗粒减少肝细胞凋亡和炎症标志物。
- 机制与调节肠道菌群、下调DAP、抑制NOD1/RIPK2通路有关。
核心结论
- 赤丹退黄颗粒通过调节肠道菌群和下调DAP代谢物抑制NOD1/RIPK2信号通路,从而改善胆汁淤积性肝损伤大鼠的肝损伤。
研究设计与样本
- 采用ANIT诱导的SD大鼠胆汁淤积性肝损伤模型,设对照组、模型组、熊去氧胆酸组和赤丹退黄颗粒治疗组。
- 用UHPLC-Q-Orbitrap-HRMS分析赤丹退黄颗粒的血中成分,通过肝功能检测、HE和TUNEL染色、透射电镜、ELISA、转录组学、RT-qPCR、Western blot、免疫组化和免疫荧光评估疗效与机制。
- 进一步检测赤丹退黄颗粒对肠道菌群及其相关代谢物meso-2,6-二氨基庚二酸(DAP)的影响,并通过体外实验验证。
主要发现
- 模型组大鼠血清AST、ALT、ALP、TBA、TBIL和DBIL水平显著升高,肝组织见炎症细胞浸润、肝细胞变性和坏死。
- 赤丹退黄颗粒给药显著改善肝功能和胆汁淤积指标。
- 透射电镜和TUNEL染色显示赤丹退黄颗粒治疗显著减少肝细胞凋亡。
- ELISA结果显示赤丹退黄颗粒有效降低炎症标志物。
- 转录组分析显示赤丹退黄颗粒抑制NOD1/RIPK2通路,肝组织中NOD1、RIPK2及相关基因表达显著下降。
临床怎么用
- 赤丹退黄颗粒可能通过调节肠道菌群和抑制NOD1/RIPK2通路改善胆汁淤积性肝损伤,为临床用药提供机制依据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cholestatic liver injury (CLI), which occurs if bile acids are imbalanced and the liver becomes inflamed, is difficult to treat effectively OBJECTIVE: We investigated how the Chinese patent medicine Chidan Tuihuang granule (CDTH) ameliorates cholestatic liver injury with a focus on its effects on the NOD1/RIPK2 pathway and intestinal flora METHODS: We used an ANIT-induced SD rat model of CLI to evaluate the therapeutic effects of CDTH. The experimental design included control, model, UDCA (ursodeoxycholic acid) and CDTH treatment groups. UHPLC-Q-Orbitrap-HRMS was used to analyse the blood components of CDTH. The efficacy of CDTH was assessed by liver function tests, histopathological examination (HE and TUNEL staining), transmission electron microscopy, and ELISA to measure apoptosis and inflammatory markers. Mechanistic insights were obtained using transcriptomics and RT-qPCR, while alterations in the expression of key proteins were studied using western blotting, immunohistochemistry, and immunofluorescence. Furthermore, the impact of CDTH on the gut microbiota and its associated metabolite, meso-2,6-diaminopimelic acid (DAP), which is linked to NOD1 activation, was examined and confirmed through in vitro RESULTS: The experimental results demonstrated a notable elevation in serum levels of AST, ALT, ALP, TBA, TBIL, and DBIL in the rats belonging to the model group, accompanied by the infiltration of inflammatory cells, hepatocyte degeneration, and necrosis in the liver tissue. CDTH administration significantly improved liver function and cholestasis indicators. Transmission electron microscopy and TUNEL staining revealed a marked reduction in liver cell apoptosis with CDTH treatment. ELISA results showed that CDTH effectively reduced inflammatory markers. Transcriptomic analysis showed that CDTH inhibited the NOD1/RIPK2 pathway, resulting in a significant decrease in the expression of NOD1, RIPK2 and associated genes in liver tissue. Gut microbiota analysis demonstrated that CDTH regulated intestinal flora structure, reducing the abundance of DAP-producing Gram-negative bacteria such as lactobacilli. In vitro experiments confirmed that CDTH enhanced cell viability by downregulating the DAP-mediated NOD1/RIPK2 signaling pathway secreted by intestinal bacteria CONCLUSION: CDTH ameliorated liver damage in cholestatic rats by inhibiting the NOD1/RIPK2 signaling pathway through regulation of gut flora and downregulation of DAP metabolites.
引用
- Chen Y, Hu Q, Zhang W, et al. Chidan Tuihuang granule modulates gut microbiota to influence NOD1/RIPK2 pathway in cholestatic liver injury recovery. Phytomedicine. 2024. PMID: 39461197. doi:10.1016/j.phymed.2024.156164
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。